IκB-ζ Inhibitors

The chemical class of IκB-ζ inhibitors encompasses a variety of compounds that target specific steps in the NF-κB signaling pathway, thereby modulating IκB-ζ activation and function. BAY 11-7082 is an inhibitor that directly blocks IκB-ζ phosphorylation, preventing its release and nuclear translocation. TPCA-1 inhibits IKK-2, an upstream kinase involved in IκB-ζ phosphorylation, thereby indirectly modulating IκB-ζ activity. sc-514, a selective COX-2 inhibitor, indirectly affects IκB-ζ by modulating the COX-2/PGE2 pathway, leading to reduced activation of the NF-κB signaling cascade. JSH-23 disrupts the nuclear translocation of NF-κB subunits, including IκB-ζ, and impedes its role in gene expression. Natural compounds like Withaferin A and Wedelolactone inhibit NF-κB activation, impacting IκB-ζ-mediated signaling.

Bay 11-7085, an analog of BAY 11-7082, shares similar inhibitory effects on NF-κB activation and IκB-ζ phosphorylation. Parthenolide and Andrographolide, natural products with anti-inflammatory effects, inhibit NF-κB activation, indirectly affecting IκB-ζ-mediated signaling. Celastrol, another natural product, modulates IκB-ζ by inhibiting the NF-κB pathway. Dehydroxymethylepoxyquinomicin inhibits proteasome function, blocking the degradation of IκB-ζ and leading to its cytoplasmic retention. QNZ (EVP4593), a potent NF-κB inhibitor, indirectly modulates IκB-ζ by inhibiting its phosphorylation and subsequent degradation. These inhibitors, with their diverse modes of action, provide valuable tools for dissecting the complex regulatory mechanisms governing IκB-ζ function.